Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study

Maryse C. Cnossen1*, Jilske A. Huijben1, Mathieu van der Jagt2, Victor Volovicic1,3, Thomas van Essen4, Suzanne Polinder1, David Nelson5, Ari Ercole6, Nino Stocchetti7,8, Giuseppe Citerio9,10, Wilco C. Peul4,11, Andrew I. R. Maas12, David Menon6, Ewout W. Steyerberg1,13, Hester F. Lingsma1 on behalf of the CENTER-TBI investigators

Abstract

Background: No definitive evidence exists on how intracranial hypertension should be treated in patients with traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients with TBI.

Methods: A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study.

Results: The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals (n = 60, 91%) and designated level I trauma centers (n = 44, 67%). The Brain Trauma Foundation guidelines were used in 49 (74%) centers. Approximately 90% of the participants (n = 58) indicated placing an ICP monitor in patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications or on peri-insertion precautions. We found wide variation in the use of first- and second-tier treatments for elevated ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and treatment (n = 32, 48%), whereas the others were considered more conservative (n = 34, 52%).

Conclusions: Substantial variation was found regarding monitoring and treatment policies in patients with TBI and intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma centers and provide an opportunity and necessity for comparative effectiveness research.

Keywords: Traumatic brain injury, Intracranial hypertension, ICP, ICU, Comparative effectiveness research, Survey

* Correspondence: m.c.cnossen@erasmusmc.nl

1 Center for Medical Decision Making, Department of Public Health, Erasmus MC, Rotterdam, The Netherlands

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Secondary brain injury associated with elevated intracranial pressure (ICP) is an important cause of mortality and morbidity in patients with severe traumatic brain injury (TBI) [1]. Therefore, identifying high ICP and optimizing its management is believed to be critically important. Yet, no definitive evidence exists on how ICP should be monitored and treated [2]. Patient and treatment heterogeneity make conducting randomized controlled trials (RCTs) challenging. On one hand, the majority of RCTs done to date have produced nonsignificant findings [3]. On the other hand, observational studies, which are easier to conduct, are at risk for confounding by indication, hammering causal inference [4, 5].

In the absence of conclusive evidence, treatment policy is usually based on local practices, individual preferences, and resource availability [6–9]. It is likely that centers and practitioners individually balance potential benefits and risks of different ICP management strategies, which may result in some centers being relatively aggressive and others being more conservative in their treatment policies.

A novel and promising approach in estimating treatment effectiveness is to exploit the existing variation by comparing standard practices between different centers or countries, which is referred to as comparative effectiveness research (CER) [10, 11]. The Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study (grant 602150) is currently recruiting and will use CER methodology to study treatment effectiveness of ICP management [10]. As a first step, we examined self-perceived practices of ICP monitoring and associated treatment policies by sending a survey to the centers participating in the CENTER-TBI study. Because previous European survey studies that addressed ICP management were published more than 10 years ago [12, 13], this study will provide an up-to-date overview of ICP management in Europe. Topics identified as showing substantial between-center variation that are plausibly associated with patient outcome will be selected for CER, and their treatment effectiveness can be studied once the CENTER-TBI patient-level data become available.

Methods
Study sample
All centers participating in the prospective, longitudinal, observational CENTER-TBI study (https://www.center-tbi.eu/) were asked to complete a set of questionnaires on structures and processes of care for patients with TBI. Questionnaires were sent to 71 centers in 20 countries between 2014 and 2015 [14]. Three centers dropped out of the CENTER-TBI study, resulting in 68 eligible centers from Austria (n = 2), Belgium (n = 4), Bosnia and Herzegovina (n = 2), Denmark (n = 2), Finland (n = 2), France (n = 7), Germany (n = 4), Hungary (n = 2), Israel (n = 2), Italy (n = 9), Lithuania (n = 2), Latvia (n = 3), The Netherlands (n = 7), Norway (n = 2), Romania (n = 1), Serbia (n = 1), Spain (n = 4), Sweden (n = 2), the United Kingdom (n = 9), and Switzerland (n = 1).

Questionnaire development and administration
A set of questionnaires designed to measure structure and process of TBI care was developed on the basis of available literature and expert opinion. These questionnaires were comprehensively described in a previous publication [14]. Pilot testing was undertaken in 16 of the participating centers, and feedback was incorporated into the final questionnaire design. One of the questionnaires contained 29 questions on ICP monitoring and treatment at the intensive care unit (ICU) (Additional file 1). In most questions, we explicitly asked for the “general policy,” which was defined as the treatment or monitoring modality estimated to be used in more than 75% of patients, recognizing that there might be exceptions. In some questions, we asked for quantitative estimations. The representatives of the centers could indicate how often they used a particular monitoring or treatment strategy (never = 0–10%, rarely = 10–30%, sometimes = 30–70%, frequently = 70–90%, always = 90–100%). The options “frequently” and “always” were interpreted as representing the general policy, in line with a previous report [15]. All definitions used in the questionnaire are described in Additional file 2.

Analyses
We calculated frequencies and percentages for all variables related to the number of responders for that variable. We examined factors associated with a relatively aggressive ICP monitoring and treatment strategy with the chi-square test or Fisher’s exact test as appropriate. Centers were classified as being relatively aggressive if they (a) place an ICP monitor in patients with a Glasgow Coma Scale (GCS) score ≤ 8 and an abnormal head computed tomographic (CT) scan, and (b) if they generally perform at least one of three second-tier treatments that represent a maximum therapy intensity (barbiturates, decompressive craniectomy, and hypothermia < 35 °C) [16].

We examined whether there were differences between and within geographic regions in the use of first- and second-tier treatments. Countries were divided into seven geographic regions (Northern Europe, Western Europe, United Kingdom, Southern Europe, Eastern Europe, Baltic states, and Israel). Within each region, we examined the percentage of centers which indicated that the particular treatment was their general policy. In addition, we assessed the influence of geographic region on treatment decision by performing logistic regression analysis with treatment as the dependent variable (general
policy yes/no) and geographic region (categorical variable) as an independent variable. The Nagelkerke $R^2$ was reported, representing the proportion of variation in treatment that can be explained by geographic region. Analyses were performed using IBM SPSS Statistics version 21 software [17].

Results
Participating centers
Sixty-six centers (97% response rate) completed the questionnaire on ICP monitoring and treatment in patients with severe TBI. Questionnaires were completed mainly by intensive care physicians ($n = 33, 50$%) and neurosurgeons ($n = 23, 35$%). Most centers ($n = 60, 91$%) had an academic affiliation, and 44 (67$%) were designated level I trauma centers (see Additional file 2 for definitions). Centers had a median of 33 (IQR 22–44) ICU beds in total and treated a median of 92 (IQR 52–160) patients with severe TBI annually. Forty-three (65$%) centers had adopted a “closed” ICU model, which is defined as an ICU model where a critical care physician (intensivist) is primarily responsible for the delivery of care for patients at the ICU [18]. An “open” model, defined as an ICU model where the admitting physician (e.g., neurosurgeon) is primarily responsible for the care of ICU patients, was adopted in three (5$%) centers [18]. A “mixed” model, which is an ICU model where the admitting physician is primarily responsible but the care is provided by a critical care physician, was adopted in 20 (30$%) centers. Approximately half ($n = 39$) of the centers had a dedicated neurosciences ICU. Approximately three-fourths of sites ($n = 49, 74$%) indicated that they used the 2007 Brain Trauma Foundation (BTF) guidelines or institutional guidelines that were based on the BTF guidelines.

Indications for ICP monitoring
The majority of participants ($n = 58, 91$%) indicated that they would generally place an ICP monitor in patients with GCS $\leq 8$ and CT abnormalities (Fig. 1). ICP monitors were less often considered for other indications, such as GCS $\leq 8$ without CT abnormalities ($n = 15, 23$%), inability to assess a patient with CT abnormalities clinically (e.g., due to sedatives; $n = 11, 17$%), and intraventricular hemorrhage ($n = 21, 33$%). Around one-third of the participants would place an ICP monitor in patients with polytrauma (GCS > 8) who require extracranial surgery or mechanical ventilation but would not otherwise have an indication for ICP monitoring. Patient-specific reasons for not monitoring ICP included when the risk of raised ICP was considered low ($n = 40, 62$%), patients were considered unsalvageable ($n = 37, 57$%), or GCS was > 8 ($n = 37, 57$%) (Additional file 2).

![Fig. 1 Indications for ICP monitoring placement. Shown are the percentages of centers that indicated that they would generally place an ICP monitor in patients with the described characteristics. Question was completed by 64 of 66 centers. CT Computed tomographic, GCS Glasgow Coma Scale, ICP Intracranial pressure.](image-url)
Variability in monitoring and treatment of intracranial hypertension
There is large variation in monitoring and treatment characteristics among European centers treating patients with TBI (Fig. 2a and b).

Parenchymal and ventricular ICP devices
Both parenchymal and ventricular ICP devices were available in more than half of centers (n = 38, 59%). One-third (n = 21) of the participants indicated that they used only parenchymal monitors, whereas five (8%) participants indicated that they used only ventricular catheters. In centers that used both types of monitors, parenchymal monitors were typically used routinely, with ventricular catheters placed either when the ventricles were enlarged or when cerebrospinal fluid (CSF) drainage was indicated. When a ventricular drain was used, half of the participants indicated that their local practice was generally to leave the drain open (n = 19, 50%), and the other half indicated a policy of intermittent drainage (n = 19, 50%) (Fig. 2a).

Precautions with ICP monitor placement
Half of the participants (55% ventricular catheter and 43% parenchymal sensor) indicated that they generally administered prophylactic antibiotics prior to the insertion of an ICP monitor, which was continued in around 10% of the centers. The majority of participants (n = 50, 77%) generally assessed the patient’s coagulation status prior to ICP monitor insertion. There was wide variability regarding the minimum international normalized ratio and minimum platelet count considered safe for device insertion (Fig. 2a).

Additional neuromonitoring
Half of the participants (n = 33) indicated that they generally used at least one additional neuromonitoring device (Additional file 2). Transcranial Doppler was generally applied in 24 (38%) centers, and brain tissue oxygenation was used in 12 (19%) centers.

First-tier treatment of elevated ICP
The majority of participants indicated an ICP threshold for medical treatment > 20 mmHg (n = 54, 83%) (Fig. 2b). There was less consensus on cerebral perfusion pressure (CPP) treatment thresholds; 39 participants (59%) indicated a threshold of 60 mmHg in their center, whereas 25 (38%) indicated individualized CPP targets.

Propofol (n = 54, 83%), midazolam (n = 48, 75%), fentanyl (n = 37, 58%), and morphine (n = 32, 51%) were generally used as part of first-tier treatment in patients with elevated ICP, whereas the use of α₂-agonists (n = 10, 16%) and barbiturates (n = 12, 19%) was less frequent (Fig. 2b and Additional file 2). Neuromuscular blocking agents were generally used in 16 (25%) centers. Participants typically preferred a specific combination of sedatives and analgesics as part of first-tier treatments: 50 participants (76%) indicated they used two to four of eight sedatives and analgesics as general policy and the other interventions only infrequently (Additional file 2).

Regarding the use of osmotic therapy, two-thirds of the participants indicated generally using mannitol (n = 43, 65%) and/or hypertonic saline (n = 44, 67%). Seventeen participants indicated the use of mannitol, but not hypertonic saline, as their general policy, whereas 18 participants indicated the opposite. Fourteen (22%) participants indicated generally using hypertonic saline in conjunction with mannitol (Fig. 2b). Crystalloids were the most commonly used intravenous fluids to augment CPP (n = 60, 91%), whereas other fluids (starches, albumin, and other combinations) were less often used (12–23%). Vasopressors were generally used in almost all centers to support CPP (n = 63, 96%). Among the parameters used to titrate vasoactive drugs, mean arterial pressure targets (n = 51, 77%) and transpulmonary thermodilution monitoring by means of pulse contour cardiac output (n = 35, 53%) were most often used (Additional file 2).

Second-tier treatments for refractory intracranial hypertension
Among the second-tier treatments, decompressive craniectomy (n = 26, 39%), barbiturates (n = 21, 32%), and CSF drainage (n = 22, 33%) were the most often employed (Fig. 2b). Hypothermia and hyperventilation (partial pressure of carbon dioxide < 30 mmHg) were the general policy in 24.6% and 15.4% of the centers, respectively, whereas approximately one-third of the participants indicated never using hypothermia and hyperventilation (Additional file 2). Participants typically preferred one (n = 27, 42%) or two (n = 20, 31%) second-tier treatments and indicated use of the other options infrequently (Additional file 2). Details on indication, administration, and targets of second-tier treatments are presented in Additional file 2 and show a high degree of variability.

Factors associated with aggressive monitoring and treatment policies
Around half of the centers were classified as using an aggressive ICP monitoring and treatment policy (n = 32, 48%). Centers with an open or mixed ICU model more often applied an aggressive ICP management style in comparison to centers with a closed ICU model (p = 0.05). We did not find significant associations between aggressiveness and any of the other factors studied (Table 1).
### Parenchymal monitor

| Chosen in the following situations | (35) |
|----------------------------------|------|
| Routine in our department        | N= 24 (68%) |
| Not routine but small ventricles  | N= 10 (29%) |
| Failed implantation of catheter  | N= 1 (3%) |

Start prophylactic antibiotics | (61) | N= 26 (43%) |

Continue Prophylactic antibiotics | (60) | N= 5 (8%) |

Assess a coagulation panel | (65) | N= 50 (77%) |

### Ventricular catheter

| Chosen in the following situations | (35) |
|----------------------------------|------|
| Routine in our department        | N= 5 (14%) |
| Not routine but enlarged ventricles | N= 9 (26%) |
| External CSF drainage             | N= 21 (60%) |
| Low cost                          | N= 1 (3%) |

Start prophylactic antibiotics | (58) | N= 32 (55%) |

Continue Prophylactic antibiotics | (57) | N= 6 (11%) |

Assess a coagulation panel | (66) | N= 50 (77%) |

### ICP monitoring

| Who inserts the ICP probe | (64-65) |
|---------------------------|--------|
| Neurosurgeon              | N= 50 (77%) |
| Neurosurgical resident    | N= 52 (82%) |
| Intensivist               | N= 1 (2%) |
| Neurointensivist          | N= 4 (6%) |

| Reference point ICP catheter |
|-----------------------------|
| Foramen of Monro           | N= 55 (83%) |
| Other^                       | N= 11 (17%) |

| Minimum INR | (65) |
|-------------|------|
| <1.4        | N= 21 (33%) |
| <1.3        | N= 17 (26%) |
| <1.2        | N= 8 (12%)  |
| Surgeon     | N= 15 (23%) |
| Other^       | N= 4 (6%)  |

| Minimum platelet count | (65) |
|------------------------|------|
| >150K                  | N= 1 (2%) |
| >110K                  | N= 30 (46%) |
| >80K                   | N= 9 (14%) |
| >50K                   | N= 9 (14%) |
| Surgeon                | N= 13 (20%) |
| Other^                 | N= 3 (4%)  |

### Treatment indications

| ICP threshold | First line (65) | Second line (58) |
|---------------|----------------|-----------------|
| >15 mmHg      | N= 3 (6%)      | Decompressive craniectomy |
| >20 mmHg      | N= 64 (83%)    | Ne= 0 (0%)       |
| >30 mmHg      | N= 6 (9%)      | Ne= 7 (11%)      |
| Individualized| N= 2 (3%)      | Ne= 5 (8%)       |

| Sedatives and analgesics |
|--------------------------|
| Fentanyl (64)            | N= 37 (58%)  |
| Midazolam (64)           | N= 48 (75%)  |
| Morphine/ epidoids (63)  | N= 32 (51%)  |
| Propofol (65)            | N= 54 (83%)  |
| Neuromuscular            | N= 15 (23%)  |
| Alfaw 2 agonist (64)     | N= 10 (16%)  |
| Barbiturates (64)        | N= 12 (19%)  |
| Other^ (66)              | N= 10 (15%)  |

| CPP support |
|-------------|
| IV fluids (66) |
| Crystalloids N= 60 (91%) |
| Colloids (starches) N= 10 (15%) |
| Colloids (albumin) N= 15 (23%) |
| Other combinations N= 8 (12%) |

| Vasoactive drugs (66) |
|------------------------|
| Mannitol (65) N= 43 (66%) |
| Hypertonic N= 44 (68%) |

| Hyperosmolar therapy |
|----------------------|
| Mannitol (43) HS (44) |
| Mannitol (65) HS (66) |

| Target temperature for hypothermia (45) |
|------------------|
| > 33°C            | N= 5 (11%) |
| 33°C or 34°C      | N= 9 (20%) |
| 32°C              | N= 1 (2%)  |
| Patient^          | N= 13 (29%) |
| physician         | N= 2 (5%)  |

| Concomitant measures in case of barbiturates use (63) |
|--------------------------------------------------------|
| Continuous EEG N= 10 (16%) |
| Serum levels   N= 12 (19%) |
| EEG and serum levels N= 6 (9%) |
| ICP control    N= 27 (43%) |
| ICP control and EEG N= 32 (51%) |
Influence of geographic region on treatment decisions

The use of first- and second-tier treatments varied substantially within and between geographic regions (Table 2). Morphine and CSF drainage showed the largest within-region variation, with approximately half of the participants within each region stating they generally use these treatments. Between-region differences were especially pronounced for barbiturates as first-tier treatment. Barbiturates were used mainly in the Baltic states and Eastern Europe, and geographic region explained 63% of the variance in barbiturate use. In addition, the use of mannitol varied substantially across regions, with all participants in the Baltic states, Eastern Europe, and Israel indicating they generally use mannitol, whereas only 11% of the participants in Northern Europe stated they generally use mannitol. In Northern Europe, Western Europe, and the United Kingdom, propofol, midazolam, morphine, and hypertonic saline are generally applied as first-tier treatment, whereas participants in Southern Europe, the Baltic states, and Eastern Europe also indicated they generally use fentanyl, barbiturates, CSF drainage, and mannitol.

Discussion

We found substantial variation in the general approaches to ICP monitoring and treatment among 66 European neurotrauma centers. The majority of centers indicated that they would insert an ICP monitor in patients with severe TBI and head CT abnormalities. There was no consensus on other indications, however, nor was there consensus on peri-insertion precautions. The use of both first- and second-tier treatments for elevated ICP varied widely between centers and regions. We found that half of the centers employed a relatively aggressive ICP management approach, and the other half reported using a more conservative approach.

Strengths of this study include the high response rate (97%), the extensive development process of the questionnaire, and the comprehensive examination of both monitoring and treatment. In addition, because our survey was completed by centers that are currently collecting patient-level data for the CENTER-TBI study, the results of this study can be used directly as input for the CER analyses once the patient-level data become available. A limitation of our study is that the included centers represent a select group of European neurotrauma centers that are prominent in the field of neurotrauma care and research. Consequently, the picture obtained might be skewed. In addition, this study is dependent on perceived practices rather than on clinical data. Although we repeatedly emphasized confidentiality of results, we cannot exclude that some physicians presented (even subconsciously) a more favorable image or presented individual treatment preferences rather than the general policy in a center. This can be explored when individual patient-level data are available. A further limitation is that we asked for isolated general treatments but did not assess specific combinations. In clinical practice, however, different treatments are used simultaneously, and outcome might be determined by the combination of treatments provided rather than by one particular intervention.

The substantial variation in strategies for ICP management in our study was in line with previous survey studies in Europe [12, 13] and the United States [15]. For example, Hesdorffer et al. [15] found that mannitol, hypertonic saline, and hyperventilation were generally used in half of their centers. Guidelines have been proposed to reduce treatment variation in medicine [19]. Although there has been an increase in protocolization of medicine and awareness of guidelines during the last decade, variation in ICP management may not have been reduced [12, 13]. Moreover, some participants claimed using treatments that are discouraged in the BTF guidelines. For example, one-fifth of the participants specified using barbiturates as first-tier treatment, whereas this is a second-tier treatment in the BTF guidelines [20]. The discrepancy between BTF guidelines and reported policies indicates that there is little

(See figure on previous page.)

Fig. 2 a Algorithm for ICP management: ICP monitoring. The blue box represents ICP monitoring with the policy of parenchymal monitor on the left and ventricular catheter on the right. Orange boxes are checkpoints during the ICP monitoring process. The N value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. 1 Centers that indicated these situations as the top one of the top three reasons for choosing a ventricular or parenchymal catheter. 2 Frequently and always summed. 3 Arterial blood pressure, midauricular level, ventricular motor, not applicable (we use only parenchymal monitors), room air, calibrated by device and meatus externa. 4 Prior to insertion of ventricular catheter for ICP monitoring. 5 Depending on other factors, such as the use of platelet aggregation inhibitors. 6 Multiple use and rotational thrombelastometric analysis prior to surgery if concerns. b Algorithm for ICP management: treatment indications, first- and second-tier treatment. The red box represents ICP treatment with first-tier treatment on top and second-tier treatment at the bottom. Orange boxes are checkpoints during the ICP treatment process. The N value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. 1 Decompressive craniectomy is (almost) never performed in our hospital. 2 Multiple answers were possible. 3 Only if ventricles are enlarged. 4 Frequently and always summed. 5 Clonidine or dexmedetomidine. 6 Sufentanil (4), remifentanil (2), β-blockers (1), alfentanil (2), esketamine (1). 7 Standard continuous infusion. 8 PaCO2 < 30 mmHg. 9 Variable, depends on patient. 10 Variable, depends on physician. CPP Cerebral perfusion pressure, CSF Cerebrospinal fluid, EEG Electroencephalogram, HS Hypertonic saline, ICP Intracranial pressure, INR International normalized ratio, IV Intravenous, PaCO2 Partial pressure of carbon dioxide
consensus among neurotrauma centers with respect to ICP management. This might be due to the relatively small evidence base underpinning the guidelines [3].

Our study has several implications for the planned CER analyses. We found wide variation for most of the topics studied, which enables analyzing effectiveness of ICP management at the hospital level. Analyzing effectiveness at the hospital level might be especially useful for treatments that were indicated to be used “rarely,” “sometimes,” or “frequently” by the large majority of participants. For these treatments, patient characteristics play an important role, and these can dramatically confound conventional patient-level analyses [4, 5]. Caution should be applied, however, in the interpretation of the effects of treatments that are performed solely in some regions and not in others. For example, barbiturates are often used as first-tier treatment in the Baltic states and Eastern Europe but not in other regions. A harmful or beneficial effect could therefore also be attributed to other aspects of care in the particular regions rather than to barbiturate use itself. In principle, it is possible to adjust statistically for between-center differences other than the treatment variable of interest with a random-effects model with a random intercept for center. However, when correlations between the treatment variable of interest and other factors that differ between centers are strong, such as for the first-line use of barbiturates and region, this might not be sufficiently captured by the random-effects model. In such a case, differences in outcome cannot be attributed with certainty to the treatment under study.

### Table 1 Factors associated with an aggressive ICP management style

| Factor                        | Relatively aggressive centers (n = 32) | Relatively conservative centers (n = 34) | p Value |
|-------------------------------|--------------------------------------|----------------------------------------|---------|
| ICU organization              |                                       |                                        |         |
| Closed                        | 17 (40%)                             | 26 (60%)                               | 0.05    |
| Open/mixed                    | 15 (65%)                             | 8 (35%)                                |         |
| Dedicated neurosciences ICU   |                                       |                                        | 0.96    |
| Available                     | 19 (49%)                             | 20 (51%)                               |         |
| Not available                 | 13 (48%)                             | 14 (52%)                               |         |
| BTF guidelines used\(a\)      |                                       |                                        | 0.48    |
| Yes                           | 25 (51%)                             | 24 (49%)                               |         |
| No                            | 7 (41%)                              | 10 (59%)                               |         |
| Volume\(b\)                   |                                       |                                        | 0.82    |
| High volume                   | 17 (47%)                             | 19 (53%)                               |         |
| Low volume                    | 15 (50%)                             | 15 (50%)                               |         |
| Country's income level\(c\)   |                                       |                                        | 0.83    |
| High income                   | 27 (49%)                             | 28 (51%)                               |         |
| Relatively low income         | 5 (46%)                              | 6 (54%)                                |         |
| Geographical location\(d\)    |                                       |                                        | 0.84    |
| Northern Europe               | 4 (44%)                              | 5 (56%)                                |         |
| Western Europe                | 13 (52%)                             | 15 (48%)                               |         |
| United Kingdom                | 3 (43%)                              | 4 (57%)                                |         |
| Southern Europe               | 5 (42%)                              | 7 (58%)                                |         |
| Baltic states                 | 2 (40%)                              | 3 (60%)                                |         |
| Eastern Europe                | 3 (50%)                              | 3 (50%)                                |         |
| Israel                        | 2 (100%)                             | 0 (0%)                                 |         |

\(\text{BTF Brain Trauma Foundation, ICU Intensive care unit}\)

\(a\) BTF guidelines or institutional guidelines that were broadly based on the BTF guidelines

\(b\) Relatively high volume (number of patients with severe TBI admitted to the ICU higher than the median number of patients with severe TBI admitted to the ICU \(n = 92\)) vs. relatively low volume (number of patients with severe TBI admitted to the ICU lower than or equal to the median number of patients with severe TBI admitted to the ICU)

\(c\) The division into relatively high- and low-income countries was based on a 2007 report by the European Union [21]. High income = Austria, Belgium, Denmark, Finland, France, Germany, Israel, Italy, The Netherlands, Norway, Spain, Sweden, United Kingdom, and Switzerland; relatively low income = Bosnia and Herzegovina, Bulgaria, Hungary, Latvia, Lithuania, Romania, and Serbia

\(d\) Northern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania
On the basis of our findings, we recommend prioritizing the following topics for CER because of the feasibility of the center-level approach:

1. ICP monitoring in patients with indications other than GCS ≤ 8 and CT abnormalities
2. Parenchymal vs. ventricular monitoring (with and without CSF drainage)
3. Use of first-tier treatments for elevated ICP (including use of neuromuscular blocking agents, mannitol vs. hypertonic saline vs. mannitol + hypertonic saline, fentanyl vs. no fentanyl, fluid management)
4. Use of second-tier treatments (including decompressive craniectomy vs. barbiturates vs. hypothermia)
5. The effect of an aggressive ICP management policy vs. a more conservative approach

Conclusions

Substantial variation was found in the monitoring and treatment of patients with severe TBI and intracranial hypertension. These results indicate a lack of consensus among European neurotrauma centers and provide an important opportunity and necessity for CER to support the development of optimal treatment protocols for these severely affected patients.

Additional files

- Additional file 1: Provider profiling questionnaire. (PDF 672 kb)
- Additional file 2: Detailed results. (PDF 85 kb)

Abbreviations

BTF: Brain Trauma Foundation; CENTER-TBI: Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury; CER: Comparative effectiveness research; CPP: Cerebral perfusion pressure; CSF: Cerebrospinal fluid; CT: Computed tomographic; EEG: Electroencephalogram; GCS: Glasgow Coma Scale; HS: Hypertonic saline; ICP: Intracranial pressure; ICU: Intensive care unit; INR: International normalized ratio; IV: Intravenous; PaCO₂: Partial pressure of carbon dioxide; RCT: Randomized controlled trial; TBI: Traumatic brain injury

Acknowledgements

The authors thank all clinical staff and researchers at the CENTER-TBI sites for completing the provider profiling questionnaires.

CENTER-TBI investigators and participants

Hadie Adams¹, Masala Alessandro², Judith Allanson³, Krisztina Amrein⁴, Norberto Andaluz⁵, Nada Andelic⁶, Nanna Andreassen⁷, Audny Anke³, Anna Anton³, Hildo Ardon⁵, Gérard Audibert¹, Kaspars Auslands¹², Philippe Azouvi¹³, Camelia Baciu¹⁴, Andrew Bacon¹⁵, Rafael Badenes¹⁶, Trevor Baglin¹⁷, Ronald Bartels¹⁸, Pål Barzó¹⁹, Ursula Bauerfeind²⁰, Ronny Beer²¹, Francisco Javier Belza²², Bo-Michael Bellander²³, Antonio Belli²⁴, Remy Beller²⁵, Håblad Benat²⁶, Thierry Benazé²⁷, Maurizio Berardino²⁸, Luigi Beretta²⁹, Christopher Beynon³⁰, Federico Bilotta³¹, Harald Binder³², Erta Biqiri³³, Norberto Boccia³⁴, Jiří Borek³⁵, Milena Borres³⁶, Kaspars Būcis³⁷, Anja Büchler³⁸, Pierre Caudron³⁹, Miloš Červinka⁴⁰, Lozanno Guillermo Carbajo⁴¹, Elsa Carisse⁴², Keri Carpenter⁴³, Ana M. Castro-León⁴⁴, Francesco Causin⁴⁵, Giorgetto Chevallier⁴⁶,
43 Department of Neuroscience, Azienda Ospedaliera Università di Padova, Padua, Italy
44 Neurointensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
45 School of Medicine and Surgery, Università Milano Bicocca, Milan, Italy
46 Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands
47 Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
48 Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
49 School of Public Health and Preventive Medicine, Monash University and The Alfred Hospital, Melbourne, Australia
50 Radiology/MRI Department, MRC Cognition and Brain Sciences Unit, Cambridge, UK
51 Institute of Medical Psychology and Medical Sociology, Universitätmedizin Göttingen, Göttingen, Germany
52 Oxford University Hospitals NHS Trust, Oxford, UK
53 Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagotai Research Centre, University of Pecs, and Hungarian Brain Research Program (grant KTIA 13 NAP-A-1/8), Pecs, Hungary
54 Brain Physics Lab, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
55 Intensive Care Unit, CHR Citadelle, Liège, Belgium
56 Intensive Care Unit, CHU de Liège, Liège, Belgium
57 Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
58 Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
59 Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy
60 Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
61 Department of Neurosurgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
62 Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands
63 Department of Neurosurgery, Medical Faculty and Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
64 Department of Neurosurgery, Regional Medical Center Dr Safet Mujč, Mostar, Bosnia and Herzegovina
65 Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
66 Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary
67 Department of Neurology, Clinical Neurophysiology and Neuranaesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
68 National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, NZ
69 Rehabilitation and Brain Trauma, Turku University Central Hospital and University of Turku, Turku, Finland
70 Department of Medicine, Azienda Ospedaliera Università di Padova, Padua, Italy
71 Department of Anaesthesiology and Intensive Care, University Hospital of Northern Norway, Tromsø, Norway
72 Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
73 Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain
74 Department of Neurosurgery, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
75 Emergency Department, CHU de Liège, Liège, Belgium
76 Department of Computing, Imperial College London, London, UK
77 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and Monash University, Clayton, Australia
78 Department of Neurosurgery, Neurosciences Centre & JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
79 Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
80 Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA
81 Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
82 Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden
83 Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
84 Department of Medical Imaging, St. Olav's Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
85 Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands
86 International Neurotrauma Research Organisation, Vienna, Austria
87 National Institute for Stroke & Applied Neurosciences, Auckland University of Technology, Auckland, NZ
88 Department of Neurosurgery, University Hospital Ghent, Ghent, Belgium
89 Department of Neurosurgery, Clinical Centre of Vojvodina, Novi Sad, Serbia
90 Helsinki University Central Hospital, Helsinki, Finland
91 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
92 Hungarian Brain Research Program (grant KTIA 13 NAP-A-1/8), University of Pécs, Pécs, Hungary
93 Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
94 Department of Neurological & Spinal Surgery, Markusvonzky University Teaching Hospital, Szombathely, Hungary
95 Cyclotron Research Center, University of Liège, Liège, Belgium
96 Emergency Medicine Research in Sheffield, Health Services Research Section, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
97 Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany
98 VP Global Project Management, Central Nervous System, ICON plc, Paris, France
99 Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
100 Department of Anesthesiology & Intensive Care, University Hospitals Southhampton NHS Trust, Southampton, UK
101 IconMetrix NV, Leuven, Belgium
102 Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sports Medicine, Witten/Herdecke University, Cologne, Germany
103 Centrum für Schlaganfallforschung, Charité – Universitätsmedizin Berlin, Berlin, Germany
104 Intensive Care Unit, Southmead Hospital Bristol, Bristol, UK
105 Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
106 Department of Neurosurgery, CHU de Liège, Liège, Belgium
107 Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
108 Department of Medical Genetics, University of Pécs, Pécs, Hungary
109 National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Australia
110 Department of Health and Prevention, University Greifswald, Greifswald, Germany
111 Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania
112 Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
113 Department of Intensive Care, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands
114 Department of Systems Medicine, Steno Diabetes Center, Gentofte, Denmark
115 Analytic and Translational Genetics Unit, Department of Medicine, Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
116 Program in Medical and Population Genetics, The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
117 Department of Radiology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
118 Neurointensive Care Unit, Department of Anesthesiology & Intensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
119 International Projects Management, ARTTIC, Munich, Germany
120 Department of Anesthesiology & Intensive Care, Azienda Ospedaliera Università di Padova, Padua, Italy
121 Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Department of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
122 Intensive Care Unit, CHU Dupuytren, Limoges, France
123 Intensive Care Unit, CHRU de Besançon, Besançon, France
124 Department of Anesthesiology and Critical Care, Pituit-Salpêtrière Teaching Hospital, Assistance Publique – Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France
125 Department of Neurosurgery, Kaunas University of Technology and Vilnius University, Vilnius, Lithuania
126 Rêzego Hospital, Rêzego, Latvia
127 Department of Anesthesiology, Critical Care & Pain Medicine, NHS Lothian & University of Edinburgh, Edinburgh, UK
128 Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
129 Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway
130 Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Oslo, Norway
131 Department of Neurology, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands
132 The Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA
133 Department of Neurosurgery, Odense University Hospital, Odense, Denmark
134 Department of Neurosurgery, Vall d’Hebron University Hospital, Barcelona, Spain
135 Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
136 University Hospital Heidelberg, Heidelberg, Germany
137 Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary
138 Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands
139 Department of Anesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria
140 Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark
141 Department of Emergency Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
142 Department of Physical Medicine and Rehabilitation, St. Olavs Hospital and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
143 Neurosurgical Cooperative Holland, Department of Neurosurgery, Leiden University Medical Center and Medical Center Haaglanden, Leiden and The Hague, The Netherlands
144 Department of Neurosurgery, University of Pécs, Pécs, Hungary
145 Universitätsmedizin Göttingen, Göttingen, Germany
146 Division of Neurosciences Critical Care, John Hopkins University School of Medicine, Baltimore, MD, USA
147 Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK
148 Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
149 Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
150 Cochrane Consumers and Communication Review Group, Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.
151 Department of Rehabilitation, M. Bufalini Hospital, Cesena, Italy
152 Department of Neurosurgery, King’s College London, London, UK
153 Radiology/MRI Department, CHU de Liège, Liège, Belgium
154 Neurologie, Neurochirurgie und Psychiatrie, Chanté – Universitatsmedizin Berlin, Berlin, Germany
155 Pauls Stradins Clinical University Hospital, Riga, Latvia
156 Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
157 Director of Neurocritical Care, University of California, Los Angeles, Los Angeles, CA, USA
158 Department of Neurosurgery, St. Olav’s Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
159 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
160 Department of Psychiatry, University of Florida, Gainesville, FL, USA
161 Division of Psychology, University of Stirling, Stirling, UK
162 VTT Technical Research Centre, Tampere, Finland
163 University of Florida, Gainesville, FL, USA
164 Department of Neurosurgery, The Haga Hospital, The Hague, The Netherlands
165 Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands
166 Preventive Medicine, Monash University, Melbourne, Australia
167 Universitätsmedizin Göttingen, Göttingen, Germany
168 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
169 Department of Psychiatry, University of Florida, Gainesville, FL, USA
170 Division of Psychology, University of Stirling, Stirling, UK
171 VTT Technical Research Centre, Tampere, Finland
172 University of Florida, Gainesville, FL, USA
173 Department of Neurosurgery, The Haga Hospital, The Hague, The Netherlands
174 Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands
175 Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway
176 Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Oslo, Norway
177 Department of Neurology, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands
178 The Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA
179 Department of Neurosurgery, Odense University Hospital, Odense, Denmark
180 Department of Neurosurgery, Vall d’Hebron University Hospital, Barcelona, Spain
181 Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
182 University Hospital Heidelberg, Heidelberg, Germany
183 Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary
184 Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands
185 Department of Anesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria
186 Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark
187 Department of Emergency Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
188 Department of Physical Medicine and Rehabilitation, St. Olavs Hospital and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
189 Neurosurgical Cooperative Holland, Department of Neurosurgery, Leiden University Medical Center and Medical Center Haaglanden, Leiden and The Hague, The Netherlands
190 Department of Neurosurgery, University of Pécs, Pécs, Hungary
191 Universitätsmedizin Göttingen, Göttingen, Germany
192 Division of Neurosciences Critical Care, John Hopkins University School of Medicine, Baltimore, MD, USA
193 Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK
194 Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
195 Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
196 Cochrane Consumers and Communication Review Group, Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.
197 Department of Rehabilitation, M. Bufalini Hospital, Cesena, Italy
198 Department of Neurosurgery, King’s College London, London, UK
199 Radiology/MRI Department, CHU de Liège, Liège, Belgium
200 Neurologie, Neurochirurgie und Psychiatrie, Chanté – Universitatsmedizin Berlin, Berlin, Germany
201 Pauls Stradins Clinical University Hospital, Riga, Latvia
202 Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
203 Director of Neurocritical Care, University of California, Los Angeles, Los Angeles, CA, USA
204 Department of Neurosurgery, St. Olav’s Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
205 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
206 Department of Psychiatry, University of Florida, Gainesville, FL, USA
207 Division of Psychology, University of Stirling, Stirling, UK
208 VTT Technical Research Centre, Tampere, Finland
209 University of Florida, Gainesville, FL, USA
210 Department of Neurosurgery, The Haga Hospital, The Hague, The Netherlands
211 Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands

Funding
Data used in the preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission Seventh Framework program (602150). In addition, TVE and WCP were supported by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study.

Availability of data and materials
The datasets analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions
MCC analyzed the data and wrote the manuscript. JAH designed Fig. 2a and b. MCC, MvdJ, W, TVE, SP, DN, AE, NS, GC, WCP, ARM, DM, EWS, and HFL were involved in the development of the provider profiling questionnaires. All authors critically commented on the manuscript, and all authors read and approved the final version.

Ethics approval and consent to participate
Not applicable. There are no patients included in present study, and participating centers have given consent by completing the questionnaires.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Center for Medical Decision Making, Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. 2Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands. 3Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands. 4Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands. 5Department of Physiotherapy and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden. 6Division of Anesthesia, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK. 7Department of Pathophysiology and Transplants, University of Milan, Milan, Italy. 8Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Department of Anesthesia and Critical Care, Neuroscience Intensive Care Unit, Milan, Italy. 9School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. 10Neurointensive Care Unit, S. Gerardo Hospital, ASST-Monza, Monza, Italy. 11Department of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands. 12Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium. 13Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
References

1. Balestrelli M, Czosnyka M, Hutchinson P, Steiner LA, Hiler M, Smielewski P, Pickard JD. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. Neurocrit Care. 2006;4(1):8–13.

2. Maas AI, Menon DK, Lingsma HF, Pineda JA, Sandel ME, Manley GT. Re-orientation of clinical research in traumatic brain injury: report of an international workshop on comparative effectiveness research. J Neurotrauma. 2012;29(1):32–46.

3. Brigge F, Symnot A, Maas AI, Menoni DK, Cooper D, Rosenfeld J, Gruen RL. A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. J Neurotrauma. 2016;33(16):1461–78.

4. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9(3):199–205.

5. Bosco JL, Silliman RA, Twien SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(16):647–4.

6. Sharma S, Gomez D, de Mestral C, Hsiao M, Rutka J, Nathens AB. Emergency access to neurosurgical care for patients with traumatic brain injury. J Am Coll Surg. 2014;218(1):51–7.

7. Skoglund K, Erblad P, Marklund N. Monitoring and sedation differences in the management of severe head injury and subarachnoid hemorrhage among neurocritical care centers. J Neurosci Nurs. 2013;45(6):360–8.

8. Cnossen MC, Polinder S, Andriessen TM, van der Naalt J, Haitsma I, Horn J, Franschman G, Vos PE, Steyerberg EW, Lingsma H. Causes and consequences of treatment variation in moderate and severe traumatic brain injury: a multicenter study. Crit Care Med. 2017;45(5):660–9.

9. van Essen TA, de Rutter GC, Kho KH, Peul WC. Neurosurgical treatment variation of traumatic brain injury: evaluation of acute subdural hematoma management in Belgium and the Netherlands. J Neurotrauma. 2017;34(4):881–9.

10. Maas AI, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, Hill S, Legrand V, Sorgner A, Participants CT, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. Neurosurgery. 2015;76(1):67–80.

11. Timmons SD, Toms SA. Comparative effectiveness research in neurotrauma. Neurosurg Focus. 2012;33(1):E3.

12. Stocchetti N, Penny KJ, Dearden M, Braakman R, Cohadon F, Iannotti F, Lapierre F, Karimi A, Maas Jr A, Murray GD, et al. Intensive care management of head-injured patients in Europe: a survey from the European brain injury consortium. Intensive Care Med. 2001;27(2):400–6.

13. Erblad P, Nilsson P, Chambers I, Citerio G, Fiddes H, Howells T, Kiening K, Ragauskas A, Sahguillio J, Yau YH, et al. R3-Survey of traumatic brain injury management in European brain IT centres year 2001. Intensive Care Med. 2004;30(6):1058–65.

14. Cnossen MC, Polinder S, Lingsma HF, Maas AI, Menon D, Steyerberg EW, Investigators C-T, Participants. Variation in structure and process of care in traumatic brain injury: provider profiles of European neurotrauma centers participating in the CENTER-TBI study. PLoS One. 2016;11(8):e0161367.

15. Hesdorffer DC, Ghaier J. Marked improvement in adherence to traumatic brain injury guidelines in United States trauma centers. J Trauma. 2007;63(4):841–8.

16. Zuercher P, Groen JL, Aries MJ, Steyerberg EW, Maas AI, Ercole A, Menon DK. Reliability and Validity of the Therapy Intensity Level Scale: analysis of clinimetric properties of a novel approach to assess management of intracranial pressure in traumatic brain injury. J Neurotrauma. 2016;33(19):1768–74.

17. IBM Corporation. IBM SPSS Statistics for Windows version 21.0 software. Armonk, NY: IBM; 2012.

18. Nathens AB, Rivara FP, MacKenzie EJ, Maier RV, Wang J, Egleston B, Scharfstein DO, Junkovich GJ. The impact of an intensivist-model ICU on trauma-related mortality. Ann Surg. 2006;244(4):545–54.

19. Thomas L, Cullum N, McCollo E, Rousseau N, Soutter J, Steen N. Guidelines in professions allied to medicine. Cochrane Database Syst Rev. 2000;2:CD000349.

20. Brain Trauma Foundation, American Association of Neurological Surgeon, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24 Suppl 1:51–106.

21. European Commission. The social situation in the European Union 2007. Luxembourg: Office for Official Publications of the European Union; 2007. p. 1–220.